


PHARMACEUTICAL 2021









PHARMACEUTICAL 2021



XBiotech Inc. Rank 17 of 409



The relative strengths and weaknesses of XBiotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XBiotech Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 151% points. The greatest weakness of XBiotech Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is 190%, being 545% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	325,875
Cost of Goods Sold	34,548
Intangible Assets	0
Liabilities, Current	3,984
Liabilities, Non-Current	0
Other Assets	533
Other Compr. Net Income	1,372
Other Expenses	-1,606
Other Liabilities	1,121
Other Net Income	5,449
Property and Equipment	27,336
Research and Development	9,527
Revenues	43,997
Selling, General and Administrative Expense	18,198

Output Variable	Value in 1000 USD
Assets	353,744
Liabilities	5,105
Expenses	60,667
Stockholders Equity	348,639
Net Income	-11,221
Comprehensive Net Income	-10,535
Economic Capital Ratio	190%

